Liquidbiopsy: The Key Enabler for Rare Cell Molecular Analysis
A COMPETITIVE DIFFERENTIATOR FOR CANCER R&D PROGRAM
With the ability to deliver high-purity, high-volume rare cell sample populations that can be easily analyzed off-platform, the LiquidBiopsy system maximizes downstream process utility and makes real-time molecular data analysis a reality. The platform's automated rare cell workflow makes it a cost-effective and easy choice for a wide array of personalized cancer research projects, especially those focused on DNA and RNA sequencing from blood.
The platform leverages enhanced immunomagnetic capture within a patented microfluidic flow chip to recover rare cells from whole blood. The performance profile of the LiquidBiopsy platform immediately enables advanced molecular analysis, and serves as a front-end for NGS and PCR expression analysis, as well as for FISH and IHC and enumeration/scanning workflows. Uniquely, LiquidBiopsy-derived cell populations can be removed from the chip and directly sequenced without a need for whole genome amplification.
LIQUIDBIOPSY’S OPEN ARCHITECTURE SUPPORTS USER-DEFINED PROTOCOLS
The LiquidBiopsy cell enrichment platform is capable of processing a variety of sample inputs and supports a full suite of readout protocols for maximum analytical flexibility. The system has an open configuration that can readily be adapted to additional capture biomarkers or affinity reagents.
PARTNERING WITH INDUSTRY LEADERS AND MAJOR RESEARCH CENTERS
Cynvenio’s LiquidBiopsy technology has been validated through partnerships with major cancer centers such as UCLA’s Jonsson Comprehensive Cancer Center and USC’s Norris Cancer Center (Los Angeles, CA), Memorial Sloan-Kettering (New York, NY), and Jefferson University Kimmel Cancer Center (Philadelphia, PA).
The flexible design of the LiquidBiopsy platform supports a variety of
research areas, including:
- Stem Cell Research
- Infectious Disease
- Endothelial Cells
- Fetal Cells
- Peptide/Aptamer Libraries